Modera erate tely Mod High to e H w at ig o er h L d o M V e r y w H Tata India Pharma & Healthcare Fund o i L g (An open ended equity scheme investing in Pharma and Healthcare Services Sector) h Riskometer Investors understand that their principal As on 30th April 2021 PORTFOLIO will be at Very High Risk
INVESTMENT STYLE Company name No. of Market Value % of Company name No. of Market Value % of Primarily focuses on investment in at least 80% of its net Shares Rs. Lakhs Assets Shares Rs. Lakhs Assets assets in equity/equity related instruments of the companies in the Pharma & Healthcare sectors in India. Equity & Equity Related Total 47786.72 97.11 INVESTMENT OBJECTIVE Healthcare Services Other Equities^ 898.31 1.83 The investment objective of the scheme is to seek long Apollo Hospitals Enterprise Ltd. 70500 2254.24 4.58 Repo 1125.48 2.29 term capital appreciation by investing atleast 80% of its Fortis Healthcare Ltd. 795000 1675.07 3.40 net assets in equity/equity related instruments of the Portfolio Total 48912.20 99.40 Syngene International Ltd. 265000 1467.44 2.98 companies in the pharma & healthcare sectors in Cash / Net Current Asset 296.13 0.60 India.However, there is no assurance or guarantee that Narayana Hrudayalaya Ltd. 301420 1226.63 2.49 the investment objective of the Scheme will be Net Assets 49208.33 100.00 achieved.The Scheme does not assure or guarantee any Metropolis Healthcare Ltd. 43000 1029.87 2.09 returns. Dr. Lal Path Labs Ltd. 29000 850.48 1.73 DATE OF ALLOTMENT Healthcare Global Enterprises Ltd. 410000 728.16 1.48 December 28, 2015 Pharmaceuticals FUND MANAGER Dr Reddys Laboratories Ltd. 136000 7021.82 14.27 Meeta Shetty (Managing Since 09-Mar-21 and overall experience of 14 years) Sun Pharmaceutical Industries Ltd. 690100 4516.36 9.18 Aurobindo Pharma Ltd. 435000 4266.70 8.67 BENCHMARK Divi Laboratories Ltd. 104500 4245.16 8.63 Nifty Pharma TRI Cipla Ltd. 460000 4187.61 8.51 NAV Alkem Laboratories Ltd. 104365 2879.48 5.85 Direct - IDCW : 17.4879 Ipca Laboratories Ltd. 125426 2640.59 5.37 Direct - Growth : 17.4879 Regular - IDCW : 16.0145 Procter & Gamble Health Ltd. 26000 1657.07 3.37 Regular - Growth : 16.0145 J.B.Chemicals & Pharmaceuticals Ltd. 103000 1437.21 2.92 FUND SIZE Lupin Ltd. 123000 1315.49 2.67 Rs. 492.08 (Rs. in Cr.) Cadila Healthcare Ltd. 186000 1062.34 2.16 MONTHLY AVERAGE AUM Glenmark Pharmaceuticals Ltd. 167000 963.26 1.96 Rs. 465.65 (Rs. in Cr.) Indoco Remedies Ltd. 279000 916.52 1.86 TURN OVER Gland Pharma Ltd. 19662 546.91 1.11 Portfolio Turnover (Total) 46.98% Portfolio Turnover (Equity component only) 46.98%
EXPENSE RATIO** Direct 1.10 SIP - If you had invested INR 10000 every month Regular 2.61 **Note: The rates specified are actual month end expenses charged 1 Year 3 Year 5 Year 7 Year 10 Year Since Inception as on Apr 30, 2021. The above ratio includes the Service tax on Investment Management Fees. The above ratio excludes, proportionate charge (out of maximum 30 bps on daily average net Total Amount Invested (Rs.) 120,000 360,000 600,000 NA NA 640,000 assets allowed) in respect sales beyond T-30 cities assets, wherever applicable. Total Value as on Apr 30, 2021 (Rs.) 147,306 577,316 1,006,698 NA NA 1,072,080 VOLATILITY MEASURES^ FUND BENCHMARK Returns 45.13% 33.28% 20.85% NA NA 19.38% Std. Dev (Annualised) 20.32 26.81 Total Value of B: Nifty Pharma TRI 144,297 528,343 857,628 NA NA 906,165 Sharpe Ratio 0.26 0.15 B: Nifty Pharma TRI 39.92% 26.63% 14.28% NA NA 12.99% Portfolio Beta 0.71 1.00 R Squared 0.87 1.00 Total Value of AB: Nifty 50 TRI 148,585 472,508 872,355 NA NA 954,544 Treynor 2.13 1.16 AB: Nifty 50 TRI 47.36% 18.52% 14.98% NA NA 14.95% Jenson 0.69 NA ^Risk-free rate based on the FBIL Overnight MIBOR rate of 3.43% as (Inception date :28-Dec-2015) (First Installment date : 01-Jan-2016) on Apr 30, 2021 Past performance may or may not be sustained in the future. Returns greater than 1 year period are compounded annualized. Income Distribution cum capital For calculation methodology please refer to Pg 66 withdrawals are assumed to be reinvested and bonus is adjusted. Load is not taken in to consideration. For SIP returns, monthly investment of equal amounts invested MINIMUM INVESTMENT / on the 1st day of every month has been considered. MULTIPLES FOR NEW INVESTMENT For scheme performance refer pages 50 - 65. *B: Benchmark, AB: Additional Benchmark Rs. 5,000/- and in multiples of Re. 1/- thereafter. Source: MFI Explorer ADDITIONAL INVESTMENT/ MULTIPLES FOR EXISTING INVESTORS Rs. 1,000/- and in multiples of Re. 1/- thereafter. Top 10 Holdings Equity Sector Allocation LOAD STRUCTURE Issuer Name % to NAV Dr. Reddys Labaratories Ltd. 14.27 Entry Load : Not Applicable Sun Pharmaceutical Industries Ltd. 9.18 Pharma 78.35% Exit Load : 0.25% of NAV if redeemed/switched out before 30 Aurobindo Pharma Ltd. 8.67 days from the date of allotment. Divi Laboratories Ltd. 8.63 Cipla Ltd. 8.51 Please refer to our Tata Mutual Fund website for fundamental changes, wherever applicable Alkem Laboratories Ltd. 5.85 Ipca Labs 5.37 Healthcare Services 18.76% Apollo Hospitals Enterprise Ltd. 4.58 Fortis Healthcare Ltd. 3.40 Procter & Gamble Health Ltd. 3.37 Total 71.83 0.00% 16.00% 32.00% 48.00% 64.00% 80.00% 96.00%
Market Capitalisation wise Exposure NAV Movement
Large Cap 62.87% Tata India Pharma And Healthcare Fund - Reg - Growth 180 Nifty Pharma TRI Mid Cap 28.12% 158 136 Small Cap 9.02% 114 92 70 Market Capitalisation is as per list provided by AMFI. Apr-18 Apr-19 Apr-20 Apr-21
www.tatamutualfund.com Mutual Fund investments are subject to market risks, read all scheme related documents carefully TATA MUTUAL FUND 24